Clinical Trials Logo

Clinical Trial Summary

This is a multicentre prospective audit to determine the incidence of immunodeficiency in children with IPD. Aims and/or research question of the project 1. To determine the incidence of primary immunodeficiency in children >2 years who present with IPD 2. To determine the types of immunodeficiency associated with IPD in children


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03815357
Study type Observational
Source Murdoch Childrens Research Institute
Contact
Status Completed
Phase
Start date January 31, 2017
Completion date June 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT04561115 - A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency Phase 3
Recruiting NCT06355323 - Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France N/A
Completed NCT04566692 - A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency Phase 4
Completed NCT01465958 - Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency Phase 4
Completed NCT01581593 - Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Phase 3
Completed NCT02881437 - IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia Phase 4
Recruiting NCT06092528 - Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency N/A
Active, not recruiting NCT03576742 - Severe Immune Cytopenia Registry Www.Sic-reg.Org
Completed NCT03907241 - CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL Phase 3
Not yet recruiting NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Completed NCT02806986 - Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency Phase 3
Completed NCT03339778 - The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations N/A
Enrolling by invitation NCT00895271 - Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Recruiting NCT03206099 - NIAID Centralized Sequencing Protocol
Completed NCT02503293 - A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push Phase 4
Recruiting NCT03610802 - Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
Completed NCT02269163 - Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% Phase 3
Terminated NCT03733249 - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Phase 1/Phase 2
Completed NCT02604810 - Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency Phase 3
Not yet recruiting NCT02123615 - ASIS for GAMMAGARD in Primary Immunodeficiency Phase 1/Phase 2